Mesoporous silica nanoparticles for co-delivery of drugs and nucleic acids in oncology: A review

67Citations
Citations of this article
84Readers
Mendeley users who have this article in their library.

Abstract

Mesoporous silica nanoparticles have attracted much attention in recent years as drug and gene delivery systems for biomedical applications. Among their most beneficial features for biomedicine, we can highlight their biocompatibility and their outstanding textural properties, which provide a great loading capacity for many types of cargos. In the context of cancer nanomedicine, combination therapy and gene transfection/silencing have recently been highlighted as two of its most promising fields. In this review, we aim to provide an overview of the different small molecule drug-nucleic acid co-delivery combinations that have been developed using mesoporous silica nanoparticles as carriers. By carefully selecting the chemotherapeutic drug and nucleic acid cargos to be co-delivered by mesoporous silica nanoparticles, different therapeutic goals can be achieved by overcoming resistance mechanisms, combining different cytotoxic mechanisms, or providing an additional antiangiogenic effect. The examples here presented highlight the great promise of this type of strategies for the development of future therapeutics.

Cite

CITATION STYLE

APA

Paris, J. L., & Vallet-Regí, M. (2020, June 1). Mesoporous silica nanoparticles for co-delivery of drugs and nucleic acids in oncology: A review. Pharmaceutics. MDPI AG. https://doi.org/10.3390/pharmaceutics12060526

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free